Beverly-based Cellceutix Corp. said in a Tuesday press release that it has submitted an Investigational New Drug Application to the Food and Drug Administration for the clinical development of Prurisol as a potential new treatment for psoriasis.
What’s more, Cellceutix announced that recruitment is underway in the Phase 2b clinical trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI.
‘‘2014 has begun with our company meeting some very significant milestones in the first two months,’’ Cellceutix chief executive Leo Ehrlich said in a statement. ‘‘Our team has moved with precision to have Brilacidin enrolling patients in a mid/late-stage clinical trial only five months after we acquired it. Now the IND (the Investigational New Drug Application) for Prurisol is filed, positioning us to initiate a third clinical trial in an area of great unmet medical need.’’